Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mercator MedSystems
San Leandro, California, United Statesmercatormed.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Mercator MedSystems develops catheter-based micro-infusion technologies that enable site-specific, non-systemic drug, gene, or cell delivery directly through blood vessel walls into deep tissues. Their Bullfrog Micro-infusion Device has shown promise in early clinical trials to reduce post-thrombotic syndrome after DVT by delivering dexamethasone locally. The company’s TANGO Phase II trial demonstrated improved outcomes after below-knee arterial revascularization. Several of their devices are FDA cleared and CE marked.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- DeviceCell therapy (enabling delivery)Gene therapy (enabling delivery)Small molecule (enabling delivery)Biologic (enabling delivery)
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on Mercator MedSystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mercator MedSystems.